Enliven Therapeutics (ELVN) Times Interest Earned (2019 - 2026)
Enliven Therapeutics (ELVN) posted Times Interest Earned of -$267.53 for Q1 2026, up 8.7% sequentially from -$293.03 in Q4 2025, and up 29.94% YoY from -$205.89 in Q1 2025.
Enliven Therapeutics (ELVN) Times Interest Earned (2019 - 2026) Analysis & Trends
Enliven Therapeutics has reported Times Interest Earned for 8 years, with the latest figure at -$267.53 in Q1 2026.
- Quarterly Times Interest Earned rose 29.94% year-over-year to -$267.53 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$332.72 (up 10.07% YoY) and the FY2025 annual result came in at -$4.3, down 184.81% from the prior year.
- Times Interest Earned improved to -$267.53 in Q1 2026 per ELVN's latest filing, from -$293.03 in the prior quarter.
- Over five years, Times Interest Earned peaked at -$0.52 in Q4 2022 and troughed at -$820.9 in Q1 2023.
- A 5-year average of -$218.6 and a median of -$176.61 in 2023 frame the typical range for Times Interest Earned.
- The sharpest annual moves came in 2022 and 2024: Times Interest Earned surged 99.83% in 2022, then sank 114968.48% in 2024.
- Over 5 years, Times Interest Earned stood at -$0.52 in 2022, then retreated by 2.19% to -$0.53 in 2023, then tumbled by 114968.48% to -$611.27 in 2024, then soared by 52.06% to -$293.03 in 2025, then rose by 8.7% to -$267.53 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered -$267.53, -$293.03, and -$48.82 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Enliven Therapeutics | 4.31 Bn | 3.41 Bn | - | -19.51 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -19.51 |
| Mar 31, 2026 | -267.53 |
| Dec 31, 2025 | -293.03 |
| Sep 30, 2025 | -48.82 |
| Jun 30, 2025 | -46.55 |
| Mar 31, 2025 | -381.84 |
| Dec 31, 2024 | -611.27 |
| Sep 30, 2024 | -314.74 |
| Jun 30, 2024 | -289.45 |
| Mar 31, 2024 | -305.73 |
| Dec 31, 2023 | -0.53 |
| Sep 30, 2023 | -57.32 |
| Jun 30, 2023 | -176.61 |
| Mar 31, 2023 | -820.90 |
| Dec 31, 2022 | -0.52 |
| Sep 30, 2022 | -41.42 |
| Jun 30, 2022 | -20.26 |
| Mar 31, 2022 | -39.63 |
| Dec 31, 2021 | -311.61 |
| Sep 30, 2021 | -53.78 |